华海药业：产品注射用尼可地尔取得注册证

Group 1 - The core point of the article is that Huahai Pharmaceutical has received approval from the National Medical Products Administration for the injection of Nicorandil, which is a significant development for the company [1] - Huahai Pharmaceutical's revenue composition for the year 2024 is as follows: finished drug sales account for 60.32%, raw materials and intermediates sales account for 38.19%, technical services account for 0.66%, other businesses account for 0.55%, and other industries account for 0.28% [1] - As of the report, Huahai Pharmaceutical has a market capitalization of 27.8 billion yuan [1]